DSC09651.jpg
DSC09674.jpg
DSC09651.jpg

Leadership New


Leadership

SCROLL DOWN

Leadership New


Leadership

DSC_9781 (3).JPG

Daniel C. Siu

Founder and CEO

Mr. Siu is the founder and CEO of Rainbow Genomics. He brings 28 years of experience in genetics and life science business to the company.  

Prior to Rainbow, Mr. Siu co-founded Nextcode Health, a bioinformatics company spun off by Amgen and deCODE Genetics.  Nextcode was acquired by WuXi for US$65M after one year in operations.   Prior to Nextcode, Mr. Siu co-founded Axeq Technologies.   Axeq subsequently merged its 200 client accounts with Macrogen, to become the world's largest next-generation-sequencing service provider.  From 2005-2011, he was the managing director at deCODE Genetics, growing their genomic services business into a market leader worldwide.  

Mr. Siu received his B.S. in molecular biology from the University of Texas, Austin; his M.S. in bioinorganic chemistry from the University of Minnesota, Minneapolis; and his MBA from San Francisco State University. 


DSC_9643 (2).JPG

Yasushi Okazaki, M.D, Ph.D.

chief medical officer

Dr. Okazaki is a pioneer and a leader in using precision medicine and next-generation-sequencing tests for hereditary disorders and tumor care in Japan.  He currently holds multiple positions -

Dr. Okazaki is the head & professor of Diagnostics and Therapeutics of Intractable Diseases, Graduate School of Medicine, & the Intractable Disease Research Center, at Juntendo University.  

In addition, Dr. Okazaki is the facility director of RIKEN Genome Network Analysis Support Facility leading their research DNA sequencing efforts.

He is also a visiting professor at the Research Center for Genomic Medicine, Saitama Medical University.

Dr. Okazaki is a pioneer in Japan using genomics technologies in clinical care, including the applications of whole exome sequencing in pediatric and emergency neonatal care, and cancer panel sequencing for tumor profiling.  He also leads multiple cancer screening projects for Japanese patients.  Dr. Okazaki is frequently interviewed by the Japanese media and corporations, on current practices of precision medicine and how it may impact the Japanese society.

Dr. Okazaki received his M.D. from Okayama University Medical School, and his Ph.D. from Osaka University Medical School.


DSC09674.jpg

Clinical Advisory Board New


Clinical Advisory Board

Clinical Advisory Board New


Clinical Advisory Board

Dr  Binder's  Picture 2.jpg

Scott W. Binder, M.D.

Dr. Scott Binder is currently the director at the Binder Institute of Pathology, Los Angeles. Previously, he was the Pritzker Professor & Senior Vice Chair; Director, Pathology Clinical Services; and Chief, Dermatopathology at the University of California, Los Angeles.

At UCLA Health, Dr. Binder directed all of the clinical and anatomic laboratories, the Autopsy Service, the Biomarker Innovations Laboratory, the Cytogenetics Laboratory, the Molecular Pathology Laboratory and the Clinical Genomics Center.  

Dr. Binder is a nationally and internationally known dermatopathologist with one of the largest consultative practices in the country.  He receives more than 6,000 second opinion consults on difficult and challenging cases in dermatopathology from academic institutions, reference laboratories and community pathology groups from all over the country as well as international cases from Greece, China, and Korea. 

Dr. Binder has devoted a great deal of time to research in the molecular signatures of tumors with an emphasis on using unique gene expressions to diagnose and prognosticate various dermatologic neoplasms.  His working team has won two Stowell-Orbison awards at USCAP, two years in a row.  The first award concerned the use of gene signatures using microarray technology to characterize cellular neurothekeomas of the skin.  The second award was based on a study which compared metastases of melanoma with their primaries and shed light upon which genes may be important in predicting which melanomas will metastasize to sentinel lymph nodes, and thus, which melanomas may demonstrate a worse clinical prognosis.

China Experience

Dr. Binder has given many talks in China, where he was inducted to the Chinese Academy of Medical Sciences. 

Recently, Dr. Binder was introduced to a Chinese environmental testing company, CTI,  which wanted to expand into medical laboratory testing. Since then, Dr. Binder and the partners have planned a lab in Shanghai China, which will specialize in esoteric testing for clinical trials and clinical work for Chinese hospitals and other less advanced labs. The lab building, approximately 25,000 sq. ft., is being outfitted in Shanghai, and the choice of instrumentation and technologists is well underway. This lab should greatly elevate the quality of care for patients and doctors in China, and has served as an excellent springboard for learning how business is conducted in China.


WGrodyPhoto.png

Wayne W. Grody, M.D., Ph.D.

Dr. Grody is a professor in the Departments of Pathology & Laboratory Medicine, Pediatrics and Human Genetics, and the institute for Society and Genetics, at the UCLA School of Medicine.

He is the director of the Molecular Diagnostic Laboratories and the Clinical Genomics Center within the UCLA Medical Center, one of the first such facilities in the country to offer DNA-based tests for diagnosis of a wide variety of genetic, infectious, and neoplastic diseases, as well as bone marrow engraftment, patient specimen identification and paternity testing by DNA fingerprinting, and clinical genomic DNA sequencing for undiagnosed disorders.  

Dr. Grody is also an attending physician in the Department of Pediatrics, specializing in the care of patients with or at risk for genetic disorders (with a special interest in familial Mediterranean fever, among others), and director of the UCLA Intercampus Medical Genetics Training Program.  

He has been one of the primary developers of quality assurance and ethical guidelines for DNA-based genetic testing for a large number of governmental and professional agencies including the FDA, AMA, CAP, ACMG, ASHG, NCCLS/CLSI, CDC, AMP, VA, ACGME, NIH-DOE Human Genome Project (ELSI program).

  • Dr. Grody was the past president of the American College of Medical Genetics (2013-2015).

He also served -

  • For five years as the founding chair of the Advisory Committee on Genomic Medicine for the entire VA healthcare system

  • As a member of the NIH-DOE Task Force on Genetic Testing

  • As the working group chair for development of national guidelines for cystic fibrosis and factor V-Leiden mutation screening.

Dr. Grody did his undergraduate work at Johns Hopkins University, received his M.D. and Ph.D. at Baylor College of Medicine, and completed residency and fellowship training at UCLA.  He is double-board-certified by the American Board of Pathology (Anatomic and Clinical Pathology, molecular Genetic Pathology) and the American Board of Medical Genetics (Clinical Genetics, Molecular Genetics, Biochemical Genetics).


Stephen Lam.jpg

Click to enlarge

Dr. Stephen Tak Sum Lam

Between 1990-2015, Dr. Lam was the Director of Genetic Laboratory and Head of Clinical Genetic Service, Department of Health, Hong Kong.  Over these 25 years, Dr. Lam was instrumental in training many clinical geneticists and teaching physicians who are currently serving various communities in Hong Kong as clinicians and faculty members at university medical schools - Dr. Lam is often referred to as "the grandfather of medical genetics in Hong Kong" .

His main clinical activities and research are in the diagnosis and prevention of genetic diseases and ethical, legal and social issues in genetics. He has published more than 100 articles and edited two books.

Dr. Lam is currently the Director of Clinical Genetics Service and Honorary Consultant in Clinical Genetics at the Hong Kong Sanatorium and Hospital. He is also an Honorary Professor of the Faculty of Medicine in the Chinese University of Hong Kong. In addition, Dr. Lam is also -

  • Fellow of Hong Kong College of Paediatricians

  • Fellow of Royal College of Physicians of Edinburgh

  • Fellow of Hong Kong Academy of Medicine

Dr. Lam serves as Convenor of the Ethics Panel of the Hong Kong Family Planning Association and as a member on the Ethics Committee of the Council on Human Reproductive Technology in Hong Kong.  He also serves as editor of several international journals including Clinical Genetics, HUGO Journal, and Journal of Community Genetics.

Dr. Lam was also the - 

  • Founding Chairman of the Hong Kong Society of Medical Genetics in 1987, and has served incessantly on the council of this society

  • Consultant Clinical Geneticist, Director of Genetic Laboratory and Head of Clinical Genetic Service, Department of Health, Hong Kong (1990-2015).

  • Council member of the International Society for Neonatal Screening, and a serving committee member of the Chinese Genetics Society.

  • Past President of the Asia Pacific Society of Human Genetics (2011-12), and the International Federation of Human Genetic Societies (2012-14).

Dr. Lam obtained his Bachelor of Medicine and Bachelor of Surgery degrees from the University of Hong Kong in 1976. Subsequently, he was trained in Paediatrics and Clinical Genetics at Queen Elizabeth Hospital, Hong Kong and Guy's Hospital, London. For his research on Biochemical Genetics and Cytogenetics, he was awarded Doctor of Medicine in 1988. He was also awarded Master of Health Administration from the University of New South Wales in 1997.


B Lee 2014.jpg

Brendan Lee, M.D., Ph.D.

Dr. Lee is the Robert and Janice McNair Endowed Chair in Molecular and Human Genetics, Professor and Chairman of the Department of Molecular and Human Genetics at Baylor College of Medicine. 

As a pediatrician and geneticist, Dr. Lee studies structural birth defects and inborn errors of metabolism. Dr. Lee identified the first genetic causes of human skeletal dysplasias.  In the area of metabolic disease, he has developed new treatments for maple syrup urine disease and urea cycle disorders. 

Dr. Lee has been recognized by election to

  • National Academy of Medicine

  • Fellow of the American Association for the Advancement of Science (AAAS)

  • Association of American Physicians (AAP)

  • American Society for Clinical Investigation (ASCI)

  • Society of Pediatric Research (SPR).

He has also been awarded

  • American Society of Human Genetics Curt Stern Award for Outstanding Scientific Achievement

  • TAMEST Peter and Edith O’Donnell Award in Medicine

  • SPR E. Meade Johnson Award for Pediatrics Research

  • Michael E. DeBakey Excellence in Research Award

  • American Philosophical Society’s (APS) Judson Darland Prize for Patient-Oriented Clinical Investigation

  • Best Doctors in America.

Dr. Lee was previously an Investigator of the Howard Hughes Medical Institute prior to his appointment as Chair of the Department of Molecular and Human Genetics in 2014. 

The Department of Molecular and Human Genetics at Baylor College of Medicine, is the leading genetics program integrating basic, translational, clinical, and diagnostic laboratory activities.  It is composed of over 180 primary faculty members encompassing research, clinical, laboratory diagnostic, and genetic counseling missions. It ranks number one in total NIH funding and number of NIH grants. 


Jason Merker, M.D., Ph.D.

Dr. Merker is Co-Director of the Stanford Medicine Clinical Genomics Program, a joint effort between Stanford Children’s Health, Stanford Health Care, and the Stanford University School of Medicine.

The Clinical Genomics Program is a clinical and laboratory service that uses genome and exome sequencing as well as other advanced molecular testing to assist in the diagnosis of genetic disease.

Dr. Merker also directs an active research group that focuses on two areas: 1.) development of improved experimental and computational approaches related to the use of genomic sequencing and other “omics” assays for clinical care, and 2.) identification and characterization of acquired and heritable genetic variants that are important for the development of hematologic disorders and other malignancies.

Dr. Merker received his M.D. and Ph.D. in Genetics from the University of North Carolina at Chapel Hill. He then completed residency training in Clinical Pathology and fellowship training in Molecular Genetic Pathology and Clinical Cytogenetics at Stanford Hospital and Clinics, followed by post-doctoral training in cancer genomics at Stanford University.